SMA Capital’s Axsome Therapeutics AXSM Stock Holding History

SMA Capital’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.6K	Buy	84 +48	+133%	+$10.4K	0.01%	94
2026 Q1	$6.08K	Buy	+36	New	+$6.22K	﹤0.01%	79

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SMA Capital's AXSM Position: Q2 2026 in Review

SMA Capital increased its Axsome Therapeutics (AXSM) stake by 133% in Q2 2026, buying an estimated $10.4K and bringing the position to 84 shares worth $20.6K. The position accounts for 0.01% of the portfolio, ranked #94.

SMA Capital first reported a position in AXSM in Q1 2026 and has held it in 2 quarters since. 504 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

SMA Capital held 84 shares of Axsome Therapeutics worth $20.6K as of Q2 2026.
SMA Capital bought 48 Axsome Therapeutics shares in Q2 2026, an estimated $10.4K.
Axsome Therapeutics made up 0.01% of SMA Capital's portfolio in Q2 2026, its #94 holding.
SMA Capital first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 2 quarters since.
504 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.